Voices of Hope:
Real Stories from AL
Amyloidosis Warriors
Discover the transformative journeys of individuals who have bravely navigated their treatment with our groundbreaking therapy. Hear firsthand how their lives have been changed and their futures reimagined.
Patient First
ACT EARLY. LIVE BETTER
Be Proactive in AL
U.S. observed prevalence of AL Amyloidosis estimated to reach 38,563 patients by the end of 2026. No FDA approved treatments available for relapsed/refractory AL Amyloidosis
Due to its nonspecific symptoms, such as fatigue, weight loss, and swelling, the condition is often misdiagnosed or detected in later stages.
Without effective treatment, the median survival rate for AL patients with advanced cardiac involvement can be less than a year.
Our Patient First Approach
Revolutionizing Treatment
What is AL Amyloidosis?
AL Amyloidosis is a rare but serious disease that occurs when an abnormal protein called amyloid builds up in your organs and tissues. These proteins are produced in the bone marrow and can accumulate in different parts of the body, including the heart, kidneys, liver, spleen, nervous system, and digestive tract. This buildup can interfere with the normal function of these organs and can lead to severe health complications if left untreated.
Exploring New Frontiers with CAR T-Cell Therapy
At Immix Biopharma, we are pioneering a new approach to treating AL Amyloidosis using CAR T-cell therapy. This innovative treatment harnesses your own immune system to fight the disease, offering a potential curative solution where traditional treatments have failed. Early results have shown promising results, providing new hope for patients who have exhausted other options.
Extraordinary Results in Clinical Trials
Unprecedented outcomes in one of medicine’s most challenging diseases.
Our U.S. NEXICART-2 registrational trial is delivering results that are transforming the treatment landscape for relapsed/refractory AL amyloidosis.
Current Standard of Care
0%
Complete Response Rate
(Investigator’s Choice)
"An early and deep hematologic response has been found to lead to significantly prolonged survival."
Vaishali Sanchorawala, M.D.
Professor of Hematology and Oncology
Director, Amyloidosis Center at Boston University School of Medicine
0/20
Patients
Normalized disease markers
0 Days
Median Time
To response
0%
Neurotoxicity
Across all patients
4-8x
Shorter CRS
vs. other BMCA CAR-Ts